Listed company on the Beijing Stock Exchange. The main business of the company is the R&D, production and sales of raw materials and related products. The main product categories include anti-allergy, anti-thrombosis, anti-oxidation, gastric ulcer, anti-virus, antipyretic and analgesic, and ultraviolet absorbent. The main products of the company are characterized by relatively complex structure, great difficulty in research and development, high technical barriers, unique production process and high added value. The company's core management team has more than 20 years of industry experience and accumulated rich R&D technology and industrial chain resources. The company has established a long-term and stable cooperative relationship with downstream customers. The main product end market is oriented to overseas standardized markets such as Japan, South Korea, Europe and the United States. The end customers include many multinational companies and other well-known pharmaceutical enterprises.
The company's raw material of ganciclovir has obtained the GMP certificate of the State Drug Administration; Azimide has passed the API registration of NMPA and on-site GMP compliance inspection; The company and its subsidiary, Xiuyi Pharmaceutical, have obtained the certification of foreign manufacturers issued by the Japanese government; Several APIs are registered with DMF in many countries.
The company is a national high-tech enterprise, with a complete and professional research and development platform, independent intellectual property rights and advanced production technology, 13 invention patents, 19 utility model patents, and a number of invention patents in the application for authorization. Since its establishment, the company has focused on the development of its main business and scientific and technological innovation, and has been recognized as "Anhui specialized and special new small and medium-sized enterprises", "Anhui innovative pilot enterprises", "Anhui Enterprise Technology Center" and "Chuzhou Engineering Technology Research Center".
In September 2021, the company invested and set up its holding subsidiary, Hangzhou Xiaobei, and began to lay out the CDMO business of chemical raw materials and build a CDMO one-stop service platform. The company uses the professional R&D team and the rich technical experience accumulated in the research and development of production process, quality research, and safety research to gradually cultivate and develop the CDMO business of chemical raw materials, so as to further extend the industrial chain, expand the business model, and enhance the competitiveness of the company.